Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 9 de 9 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, for the EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211-22. [Ref.ID 101509]
2.Enlace a cita original Cita con resumen
Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Trajanovic M, Gebel M, Lam P, Wells PS, Prins MH. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016;127:1417-25. [Ref.ID 100222]
3.Tiene citas relacionadas Cita con resumen
Büller HR, Lensing AWA, Prins MH. Oral rivaroxaban for pulmonary embolism. Author/editor response. N Engl J Med 2012;366:2527. [Ref.ID 93327]
4.Tiene citas relacionadas Cita con resumen
Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE, on behalf of the Cassiopea Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012;379:123-9. [Ref.ID 92238]
5.Tiene citas relacionadas
Buller HR, Lensing AWA, Prins MH. Oral rivaroxaban for symptomatic venous thromboembolism. Author/editor response. N Engl J Med 2011;364:1178. [Ref.ID 90513]
6.Tiene citas relacionadas Cita con resumen
Prandoni P, Prins MH, Lensing AWA, Ghirarduzzi A, Ageno W, Imberti D, Scannapieco G, Ambrosio GB, Pesavento R, Cuppini S, Quintavalla R, Agnelli G, for the AESOPUS Investigators. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis. A randomized trial. Ann Intern Med 2009;150:577-85. [Ref.ID 85872]
7. Cita con resumen
Buller HR, Lensing AWA, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A, on behalf of the Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DTV Dose-Ranging Study. Blood 2008;112:2242-7. [Ref.ID 84553]
8.Tiene citas relacionadas Cita con resumen
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR, for the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56. [Ref.ID 81083]
9. Cita con resumen
Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA, for the ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-7. [Ref.ID 76198]
Seleccionar todas
 
 1 a 9 de 9